Ried Karin, Travica Nikolaj, Paye Yeah, Sali Avni
National Institute of Integrative Medicine (NIIM), Melbourne, VIC, Australia.
Torrens University, Adelaide, SA, Australia.
Front Nutr. 2022 May 23;9:887978. doi: 10.3389/fnut.2022.887978. eCollection 2022.
Seasonal-allergic-rhinitis (hay fever) affects approximately 4.6 million (20%) Australians each year. Hay fever manifests as runny/blocked nose and often itchy/sore/swollen eyes, with symptoms greatly impacting the quality of life. Rescue medications such as antihistamines are often needed to restore function, but they may trigger some other unwanted side effects. Probiotics have shown promise to reduce hay fever symptoms.
In this randomized double-blind placebo-controlled 12-week trial, we aimed to assess the tolerability and efficacy of the probiotic formula "NC-Seasonal-Biotic" on symptoms, quality-of-life, and immunological and microbial factors.
Adults, who had previously suffered from hay fever symptoms, were screened for eligibility and randomly allocated to probiotic or placebo trial powder. Treatment effectiveness was assessed by questionnaires, daily total-nasal-symptom-score, and weekly rhinoconjunctivitis quality-of-life questionnaire. Secondary outcome measures included immunological parameters such as T-cell immunity (Th1/Th2 ratio) and the stool-microbiome analysis. Tolerability was assessed weekly by the gastrointestinal symptom scale.
Recruitment and follow-up were challenging around the 2020/2021 hay fever season in Melbourne, Australia, due to the harsh COVID-19 restrictions and extended lockdowns. Out of the 82 adults enrolled in this study, 75% participated ( = 60), and half ( = 40) completed the 10-12-week intervention period. In the intention-to-treat analysis, no significant differences in hay fever symptoms were apparent between the groups, while quality-of-life trended toward greater improvement in the active group. Intention-to-treat analysis was confounded due to a third of all participants not completing the full 10-12-week-intervention period. Subgroup analyses of the participants ( = 40) completing the full 10-12-week study period revealed a significantly greater reduction in symptoms in the active group compared with the placebo group, including runny nose ( = 0.04) and itchy eyes ( = 0.01). Furthermore, the active group reported significant improvements in the quality-of-life, including more functionality during the day ( = 0.05), better sleep ( = 0.005), less fatigue ( = 0.04), less thirst ( = 0.007), and less irritability ( = 0.007). Immunological parameters, measured by T-helper cell ratio (Th1/Th2), improved significantly in the active group compared with the placebo group. Most microbial changes were not statistically different between the groups. The trial powder was generally well tolerated.
Our study suggests the probiotic formula "NC-Seasonal-Biotic," taken for 10-12 weeks, as effective in reducing hay fever symptoms, such as runny nose and itchy eyes, and improved the quality-of-life and immunological parameters while being well tolerated.
[www.ClinicalTrials.gov], identifier [ACTRN126200 01078943].
季节性过敏性鼻炎(花粉症)每年影响约460万(20%)澳大利亚人。花粉症表现为流鼻涕/鼻塞,眼睛常伴有瘙痒/疼痛/肿胀,这些症状严重影响生活质量。通常需要使用抗组胺药等急救药物来恢复功能,但它们可能会引发一些其他不良副作用。益生菌已显示出减轻花粉症症状的潜力。
在这项为期12周的随机双盲安慰剂对照试验中,我们旨在评估益生菌配方“NC-季节性生物制剂”对症状、生活质量以及免疫和微生物因素的耐受性和疗效。
对曾有花粉症症状的成年人进行资格筛查,并随机分配至益生菌或安慰剂试验粉剂组。通过问卷调查、每日总鼻症状评分和每周变应性鼻炎生活质量问卷评估治疗效果。次要结局指标包括免疫参数,如T细胞免疫(Th1/Th2比值)和粪便微生物群分析。每周通过胃肠道症状量表评估耐受性。
由于严格的COVID-19限制措施和延长的封锁,在澳大利亚墨尔本2020/2021年花粉症季节期间,招募和随访面临挑战。在本研究纳入的82名成年人中,75%(n = 60)参与,一半(n = 40)完成了10 - 12周的干预期。在意向性分析中,两组间花粉症症状无显著差异,而生活质量在活性组有更大改善的趋势。由于三分之一的参与者未完成完整的10 - 12周干预期,意向性分析受到干扰。对完成完整10 - 12周研究期的参与者(n = 40)进行亚组分析发现,与安慰剂组相比,活性组症状显著减轻,包括流鼻涕(P = 0.04)和眼睛瘙痒(P = 0.01)。此外,活性组报告生活质量有显著改善,包括白天功能更强(P = 0.05)、睡眠更好(P = 0.005)、疲劳更少(P = 0.04)、口渴更少(P = 0.007)和易怒更少(P = 0.007)。与安慰剂组相比,活性组通过辅助性T细胞比值(Th1/Th2)测量的免疫参数显著改善。两组间大多数微生物变化无统计学差异。试验粉剂总体耐受性良好。
我们的研究表明,服用10 - 12周的益生菌配方“NC-季节性生物制剂”可有效减轻花粉症症状,如流鼻涕和眼睛瘙痒,并改善生活质量和免疫参数,且耐受性良好。
[www.ClinicalTrials.gov],标识符[ACTRN126200 01078943]